Short Interest in Novozymes A/S (OTCMKTS:NVZMY) Decreases By 60.1%

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 12,291 shares, a decline of 60.1% from the May 14th total of 30,830 shares. Based on an average daily trading volume, of 83,894 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NVZMY. Rothschild & Co Redburn upgraded shares of Novozymes A/S to a “strong-buy” rating in a research note on Friday, March 27th. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Zacks Research upgraded shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Novozymes A/S presently has a consensus rating of “Buy”.

Novozymes A/S Stock Performance

Shares of Novozymes A/S stock traded down $0.23 during trading on Friday, hitting $59.76. 23,466 shares of the stock were exchanged, compared to its average volume of 48,196. The stock has a market capitalization of $24.77 billion, a price-to-earnings ratio of 40.38, a price-to-earnings-growth ratio of 1.12 and a beta of 0.95. The company has a fifty day moving average price of $59.39 and a 200-day moving average price of $60.41. Novozymes A/S has a 1-year low of $49.90 and a 1-year high of $75.99. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.31). The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%. As a group, equities analysts predict that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).